Valeo Financial Advisors’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Valeo Financial Advisors’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,857	Closed	-$21K	–	654
2021 Q3	$21K	Hold	1,857	–	–	﹤0.01%	567
2021 Q2	$31K	Hold	1,857	–	–	﹤0.01%	497
2021 Q1	$49K	Sell	1,857 -2,497	-57%	-$113K	﹤0.01%	879
2020 Q4	$157K	Buy	4,354 +1,021	+31%	+$36.9K	0.01%	463
2020 Q3	$118K	Buy	+3,333	New	+$145K	0.01%	436

Other funds holding EVFM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Valeo Financial Advisors's EVFM Position: Q4 2021 in Review

Valeo Financial Advisors sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q4 2021, closing a stake of 1,857 shares — an estimated $21K sold.

Valeo Financial Advisors first reported a position in EVFM in Q3 2020 and held it in 5 quarters. The position peaked at $157K in Q4 2020. 62 funds tracked by Wall St. Rank hold EVFM as of Q4 2021.

Valeo Financial Advisors reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Valeo Financial Advisors sold 1,857 Evofem Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $21K.
Valeo Financial Advisors first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
Valeo Financial Advisors's Evofem Biosciences, Inc. Common Stock position peaked at $157K in Q4 2020.
62 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q4 2021.

Based on Valeo Financial Advisors's 13F filing for Q4 2021, filed 7 Jan 2022.